Commenting on the announcement, Henry Gates, CaSE’s Director of Sector Engagement, said:

“CaSE’s strength is drawn from the solid foundation of insight and support our members give us. I am delighted to welcome LifeArc to our growing membership at an exciting time for R&D in the UK.

“LifeArc’s expertise in creating tangible benefits through the translation of discovery research will be a huge asset to CaSE as we consider how policy can best place science and engineering at the heart of the UK’s future.”

Dr Melanie Lee, LifeArc’s CEO, added:

“I am delighted that LifeArc is joining the Campaign for Science and Engineering (CaSE). Building partnerships and collaborating is central to our mission to turn research ideas into medical breakthroughs that change patient’s lives. Joining CaSE will give us the incredible opportunity to pool our knowledge and expertise with other organisations, strengthening science and research.

“LifeArc focuses on translation – working with academics to apply their research ideas to create real impact for patients. LifeArc is committed to multi-disciplinary technology teams working together to maximise patient benefit.  We offer our experience and industrial training to realise the opportunity of breakthrough science. We are looking forward to working with CaSE and other member organisations to drive meaningful changes in science and research in the UK. We look forward to making a difference together through this exciting step”.

About CaSE

The Campaign for Science and Engineering (CaSE) works to put science and engineering at the heart of the UK’s future. Our membership spans more than 115 scientific organisations, including businesses, universities, learned societies and charities, as well as individual scientists and engineers. We specialise in developing non-partisan, responsive solutions that help research and innovation to thrive in ways that improve people’s lives and livelihoods.

About LifeArc

LifeArc is a self-funded, non-profit medical research organisation. We take research ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. We have been doing this for more than 25 years and our work has resulted in five licensed medicines, including cancer drug Keytruda, and a diagnostic for antibiotic resistance.

We focus on translation – advancing lab-based scientific discoveries so they can be developed into the next generation of diagnostics, treatments and cures. We create networks of partners to tackle specific disease areas; create new funds to invest in life sciences innovation; and share our unique understanding of what it takes to advance early-stage life sciences, so that it can benefit patients and the life science ecosystem.

LifeArc is committed to spending £1.3 billion by 2030 in areas of high unmet medical need.